AR119376A1 - Compuestos heterocíclicos - Google Patents
Compuestos heterocíclicosInfo
- Publication number
- AR119376A1 AR119376A1 ARP200101928A ARP200101928A AR119376A1 AR 119376 A1 AR119376 A1 AR 119376A1 AR P200101928 A ARP200101928 A AR P200101928A AR P200101928 A ARP200101928 A AR P200101928A AR 119376 A1 AR119376 A1 AR 119376A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- halo
- aryl
- halogen
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000005915 C6-C14 aryl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- -1 cyano, hydroxy Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en la que: X es -CH₂CR³R⁴- o -CH=CR³ -, Y es -O-, -S-, -SO-, o -SO₂-, R¹ es arilo C₆₋₁₄ o heteroarilo de 5 a 14 elementos, en el que dicho arilo C₆₋₁₄ o heteroarilo de 5 a 14 elementos se sustituye opcionalmente con 1 a 5 sustituyentes seleccionados independientemente de alquilo C₁₋₆, alcoxi C₁₋₆, halo-alquilo C₁₋₆, halo-alcoxi C₁₋₆, halógeno, ciano, hidroxi y un grupo de fórmula (2), R² es hidrógeno o alquilo C₁₋₆, R³ es un grupo de fórmula (3), R⁴ es hidrógeno, halógeno o hidroxi, R⁵ es hidrógeno, halógeno, hidroxi, amino, halo-alquilo C₁₋₆, alcoxi C₁₋₆, alquilo C₁₋₆, halo-alcoxi C₁₋₆, ciano o oxo, R⁶ es hidrógeno, halógeno, arilo C₆₋₁₄, heteroarilo de 5 a 14 elementos, haloalcoxi C₁₋₆, halo-alquilo C₁₋₆, oxo, alquilo C₁₋₆, alcoxi C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₁₄ o ciano, en el que dicho heteroarilo de 5 a 14 elementos o arilo C₆₋₁₄ se sustituye opcionalmente con 1 a 2 sustituyentes seleccionados de halógeno, ciano, amino, hidroxi, alquilo C₁₋₆ y alcoxi C₁₋₆, A y B son, cada uno independientemente, heteroarilo de 5 a 14 elementos, arilo C₆₋₁₄, heterociclilo de 3 a 14 elementos o cicloalquilo C₃₋₁₄, y n y p son, cada uno independientemente, 1, 2, 3, 4 ó 5.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19185088 | 2019-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119376A1 true AR119376A1 (es) | 2021-12-15 |
Family
ID=67220669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101928A AR119376A1 (es) | 2019-07-09 | 2020-07-08 | Compuestos heterocíclicos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220242876A1 (es) |
| EP (1) | EP3997096B1 (es) |
| JP (1) | JP7649283B2 (es) |
| KR (1) | KR20220034104A (es) |
| CN (1) | CN114096545A (es) |
| AR (1) | AR119376A1 (es) |
| AU (1) | AU2020311584A1 (es) |
| BR (1) | BR112021026899A2 (es) |
| CA (1) | CA3145338A1 (es) |
| CL (1) | CL2022000019A1 (es) |
| CO (1) | CO2022000186A2 (es) |
| CR (1) | CR20220004A (es) |
| IL (1) | IL288987A (es) |
| MX (1) | MX2022000243A (es) |
| PE (1) | PE20220515A1 (es) |
| PH (1) | PH12021553249A1 (es) |
| TW (1) | TW202116781A (es) |
| WO (1) | WO2021005034A1 (es) |
| ZA (1) | ZA202110352B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| AU2019322538B2 (en) | 2018-08-13 | 2021-09-30 | F. Hoffmann-La Roche Ag | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| PL3883936T3 (pl) | 2018-11-22 | 2023-11-20 | F. Hoffmann-La Roche Ag | Nowe związki heterocykliczne |
| MX2022002311A (es) | 2019-09-12 | 2022-03-25 | Hoffmann La Roche | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl). |
| CR20230115A (es) | 2020-09-03 | 2023-04-11 | Hoffmann La Roche | Compuestos heterocíclicos |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140052034A (ko) | 2011-08-19 | 2014-05-02 | 머크 샤프 앤드 돔 코포레이션 | 신장 외수질 칼륨 채널의 억제제 |
| US9573961B2 (en) | 2012-12-19 | 2017-02-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2017087863A1 (en) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| EP3571202B1 (en) * | 2017-01-23 | 2021-06-30 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
| JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| UA126685C2 (uk) | 2017-08-29 | 2023-01-11 | Луннбек Ла-Холья Рісьоч Сенте, Інк. | Сполуки, які є модуляторами magl, і способи їх отримання і застосування |
| WO2019134985A1 (en) | 2018-01-08 | 2019-07-11 | F. Hoffmann-La Roche Ag | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| JP7669299B2 (ja) | 2019-07-03 | 2025-04-28 | エフ． ホフマン－ラ ロシュ アーゲー | 複素環モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤 |
-
2020
- 2020-07-07 JP JP2022500908A patent/JP7649283B2/ja active Active
- 2020-07-07 KR KR1020227000611A patent/KR20220034104A/ko not_active Ceased
- 2020-07-07 MX MX2022000243A patent/MX2022000243A/es unknown
- 2020-07-07 CN CN202080050165.3A patent/CN114096545A/zh active Pending
- 2020-07-07 EP EP20740259.5A patent/EP3997096B1/en active Active
- 2020-07-07 CA CA3145338A patent/CA3145338A1/en active Pending
- 2020-07-07 CR CR20220004A patent/CR20220004A/es unknown
- 2020-07-07 PE PE2021002265A patent/PE20220515A1/es unknown
- 2020-07-07 PH PH1/2021/553249A patent/PH12021553249A1/en unknown
- 2020-07-07 WO PCT/EP2020/069074 patent/WO2021005034A1/en not_active Ceased
- 2020-07-07 AU AU2020311584A patent/AU2020311584A1/en not_active Abandoned
- 2020-07-07 BR BR112021026899A patent/BR112021026899A2/pt not_active Application Discontinuation
- 2020-07-08 TW TW109123050A patent/TW202116781A/zh unknown
- 2020-07-08 AR ARP200101928A patent/AR119376A1/es not_active Application Discontinuation
-
2021
- 2021-12-13 ZA ZA2021/10352A patent/ZA202110352B/en unknown
- 2021-12-14 IL IL288987A patent/IL288987A/en unknown
-
2022
- 2022-01-04 CL CL2022000019A patent/CL2022000019A1/es unknown
- 2022-01-06 US US17/569,749 patent/US20220242876A1/en active Pending
- 2022-01-13 CO CONC2022/0000186A patent/CO2022000186A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220034104A (ko) | 2022-03-17 |
| EP3997096A1 (en) | 2022-05-18 |
| CA3145338A1 (en) | 2021-01-14 |
| IL288987A (en) | 2022-02-01 |
| JP2022539604A (ja) | 2022-09-12 |
| MX2022000243A (es) | 2022-02-03 |
| EP3997096C0 (en) | 2024-08-28 |
| PE20220515A1 (es) | 2022-04-07 |
| CN114096545A (zh) | 2022-02-25 |
| ZA202110352B (en) | 2022-08-31 |
| BR112021026899A2 (pt) | 2022-05-10 |
| PH12021553249A1 (en) | 2023-02-27 |
| CR20220004A (es) | 2022-01-31 |
| AU2020311584A1 (en) | 2022-01-20 |
| CL2022000019A1 (es) | 2022-10-21 |
| CO2022000186A2 (es) | 2022-01-17 |
| TW202116781A (zh) | 2021-05-01 |
| US20220242876A1 (en) | 2022-08-04 |
| EP3997096B1 (en) | 2024-08-28 |
| JP7649283B2 (ja) | 2025-03-19 |
| WO2021005034A1 (en) | 2021-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110405A1 (es) | Compuestos | |
| AR104884A1 (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| AR121044A1 (es) | Inhibidores de egfr | |
| AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR113842A1 (es) | Derivados de tiazol microbiocidas | |
| AR109179A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| AR113929A1 (es) | Compuestos heterocíclicos | |
| CO6321244A2 (es) | Pirrolopiridinas como inhibidores de cinasa | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| AR099789A1 (es) | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina | |
| AR120868A1 (es) | Tiofen-2-carboxamidas sustituidas y ácidos tiofen-2-carboxílicos sustituidos y sus derivados | |
| AR091208A1 (es) | Derivados de piperidina | |
| AR119790A1 (es) | Compuestos de isoxazolina y su uso como agentes para el control de plagas | |
| AR122517A1 (es) | Isoxazolidinas como inhibidores de ripk1 y usos de las mismas | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| AR115085A1 (es) | DERIVADOS DE 3-AMINO-2,4,6-TRIAZINA COMO INHIBIDORES DE LA TIROSINA CINASA DE BRUTON (Btk) | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR120864A1 (es) | Tiofenocarboxamidas sustituidas y sus derivados | |
| AR122726A1 (es) | Compuestos de unión de cereblon, composiciones de los mismos, y métodos de tratamiento con los mismos | |
| AR116906A1 (es) | Derivados de heteroarilo bicíclico | |
| AR096161A1 (es) | Derivados de triazina | |
| AR111252A1 (es) | Compuestos de isoxazol carboxamida y usos de los mismos | |
| AR092792A1 (es) | Derivados de dihidrofurano-azetadina como agentes antiparasitarios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |